Charles Schwab Investment Management Inc 9 Meters Biopharma, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.64 $132,554 - $326,288	-509,825 Reduced 82.55%	107,754 $29,000
Q4 2021 Feb 11, 2022	BUY	$0.85 - $1.33 $29,278 - $45,811	34,445 Added 5.91%	617,579 $605,000
Q3 2021 Nov 16, 2021	BUY	$1.03 - $1.41 $66,442 - $90,954	64,507 Added 12.44%	583,134 $759,000
Q2 2021 Aug 16, 2021	BUY	$1.04 - $1.5 $468,611 - $675,882	450,588 Added 662.25%	518,627 $571,000
Q1 2021 May 17, 2021	BUY	$0.84 - $2.16 $57,152 - $146,964	68,039 New	68,039 $80,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.